Orient Securities Initiates Coverage on Ascletis Pharma-B (01672) with "Buy" Rating, Sets Target Price at HK$18.38
Orient Securities has issued a research report forecasting Ascletis Pharma-B's (01672) earnings per share for 2025-2027 to be -0.32, -0.35, and -0.38 yuan, respectively. Using an absolute valuation...